<?xml version='1.0' encoding='utf-8'?>
<document id="25159194"><sentence text="Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects."><entity charOffset="0-12" id="DDI-PubMed.25159194.s1.e0" text="Pomalidomide" /></sentence><sentence text="Pomalidomide offers an alternative for patients with relapsed/refractory multiple myeloma who have exhausted treatment options with lenalidomide and bortezomib"><entity charOffset="0-12" id="DDI-PubMed.25159194.s2.e0" text="Pomalidomide" /><entity charOffset="132-144" id="DDI-PubMed.25159194.s2.e1" text="lenalidomide" /><entity charOffset="149-159" id="DDI-PubMed.25159194.s2.e2" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.25159194.s2.e0" e2="DDI-PubMed.25159194.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25159194.s2.e0" e2="DDI-PubMed.25159194.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s2.e0" e2="DDI-PubMed.25159194.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s2.e1" e2="DDI-PubMed.25159194.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s2.e1" e2="DDI-PubMed.25159194.s2.e2" /></sentence><sentence text=" Little is known about pomalidomide's potential for drug-drug interactions (DDIs); as pomalidomide clearance includes hydrolysis and cytochrome P450 (CYP450)-mediated hydroxylation, possible DDIs via CYP450 and drug-transporter proteins were investigated in vitro and in a clinical study"><entity charOffset="86-98" id="DDI-PubMed.25159194.s3.e0" text="pomalidomide" /></sentence><sentence text=" In vitro pomalidomide was neither an inducer nor inhibitor of CYP450, nor an inhibitor of transporter proteins P glycoprotein (P-gp), BCRP, OAT1, OAT3, OCT2, OATP1B1, and OATP1B3"><entity charOffset="10-22" id="DDI-PubMed.25159194.s4.e0" text="pomalidomide" /></sentence><sentence text=" Oxidative metabolism of pomalidomide was predominately mediated by CYP1A2 and CYP3A4, and pomalidomide was shown to be a P-gp substrate"><entity charOffset="25-37" id="DDI-PubMed.25159194.s5.e0" text="pomalidomide" /><entity charOffset="91-103" id="DDI-PubMed.25159194.s5.e1" text="pomalidomide" /><pair ddi="false" e1="DDI-PubMed.25159194.s5.e0" e2="DDI-PubMed.25159194.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25159194.s5.e0" e2="DDI-PubMed.25159194.s5.e1" /></sentence><sentence text=" In healthy males, co-administration of oral (4â€‰mg) pomalidomide with ketoconazole (CYP3A/P-gp inhibitor) or carbamazepine (CYP3A/P-gp inducer) did not result in clinically relevant changes in pomalidomide exposure"><entity charOffset="52-64" id="DDI-PubMed.25159194.s6.e0" text="pomalidomide" /><entity charOffset="70-82" id="DDI-PubMed.25159194.s6.e1" text="ketoconazole" /><entity charOffset="84-89" id="DDI-PubMed.25159194.s6.e2" text="CYP3A" /><entity charOffset="109-122" id="DDI-PubMed.25159194.s6.e3" text="carbamazepine" /><entity charOffset="124-129" id="DDI-PubMed.25159194.s6.e4" text="CYP3A" /><entity charOffset="193-205" id="DDI-PubMed.25159194.s6.e5" text="pomalidomide" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e0" e2="DDI-PubMed.25159194.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e1" e2="DDI-PubMed.25159194.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e1" e2="DDI-PubMed.25159194.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e1" e2="DDI-PubMed.25159194.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e1" e2="DDI-PubMed.25159194.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e1" e2="DDI-PubMed.25159194.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e2" e2="DDI-PubMed.25159194.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e2" e2="DDI-PubMed.25159194.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e2" e2="DDI-PubMed.25159194.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e2" e2="DDI-PubMed.25159194.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e3" e2="DDI-PubMed.25159194.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e3" e2="DDI-PubMed.25159194.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e3" e2="DDI-PubMed.25159194.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e4" e2="DDI-PubMed.25159194.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25159194.s6.e4" e2="DDI-PubMed.25159194.s6.e5" /></sentence><sentence text=" Co-administration of pomalidomide with fluvoxamine (CYP1A2 inhibitor) in the presence of ketoconazole approximately doubled pomalidomide exposure"><entity charOffset="22-34" id="DDI-PubMed.25159194.s7.e0" text="pomalidomide" /><entity charOffset="40-51" id="DDI-PubMed.25159194.s7.e1" text="fluvoxamine" /><entity charOffset="90-102" id="DDI-PubMed.25159194.s7.e2" text="ketoconazole" /><entity charOffset="125-137" id="DDI-PubMed.25159194.s7.e3" text="pomalidomide" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e0" e2="DDI-PubMed.25159194.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e0" e2="DDI-PubMed.25159194.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e0" e2="DDI-PubMed.25159194.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e0" e2="DDI-PubMed.25159194.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e1" e2="DDI-PubMed.25159194.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e1" e2="DDI-PubMed.25159194.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e1" e2="DDI-PubMed.25159194.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e2" e2="DDI-PubMed.25159194.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25159194.s7.e2" e2="DDI-PubMed.25159194.s7.e3" /></sentence><sentence text=" Pomalidomide appears to have low potential for clinically relevant DDI and is unlikely to affect the clinical exposure of other drugs"><entity charOffset="1-13" id="DDI-PubMed.25159194.s8.e0" text="Pomalidomide" /></sentence><sentence text=" Avoid co-administration of strong CYP1A2 inhibitors unless medically necessary" /><sentence text=" Pomalidomide dose should be reduced by 50% if co-administered with strong CYP1A2 inhibitors and strong CYP3A/P-gp inhibitors"><entity charOffset="1-13" id="DDI-PubMed.25159194.s10.e0" text="Pomalidomide" /><entity charOffset="104-115" id="DDI-PubMed.25159194.s10.e1" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.25159194.s10.e0" e2="DDI-PubMed.25159194.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25159194.s10.e0" e2="DDI-PubMed.25159194.s10.e1" /></sentence><sentence text=" " /></document>